How Online GLP-1 Prescriptions Work

You fill out a form, answer some questions about your weight and health, enter a card number, and a few days later a box shows up. It feels less like medicine than like ordering anything else online, which is exactly why it is worth understanding what is happening behind the screen.

This guide walks through each step, explains what the law requires, and gives you the questions that separate a real clinical service from a storefront with a doctor’s name on it. It is not medical advice and does not recommend any medication or dose.

Step 1: The intake questionnaire

Almost every platform starts the same way: a form asking your height, weight, medical history, current medications, allergies, and goals. Some ask about family history of thyroid cancer or pancreatitis, because those appear in GLP-1 labeling as important safety considerations.

This form is not a formality. It is the record a prescriber uses to decide whether to write a prescription, and in most states it is what legally establishes the patient-provider relationship.

Two things worth doing here:

Answer honestly, including about medications and conditions. The screening questions exist because the drug label lists real contraindications and interactions. Skipping a medication to get approved defeats the point of being screened.

Notice what the form does not ask. A form that never asks about your other prescriptions, or never asks about a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, is not doing the screening the label contemplates.

Step 2: The clinician review

Here is where state law does the work.

Semaglutide and tirzepatide are not controlled substances. That matters, because the federal rules that restrict remote prescribing of controlled drugs — the ones that shaped telehealth for ADHD medication and buprenorphine — do not apply. What governs instead is state medical practice law [1].

Two rules follow:

The prescriber must be licensed in your state. Specifically, the state where you are physically located at the time of the visit, not where you live or where the company is headquartered. A company based in New York cannot prescribe to you in Texas unless its clinician holds a Texas license. Large platforms maintain licensure in all 50 states, which is expensive; smaller ones do not, which is why availability maps differ.

Most states allow an asynchronous visit. In practice that means the prescriber reviews your questionnaire and any messages, then decides, without a real-time conversation. A minority of states require a synchronous visit — live video, sometimes audio — before a prescription can be written [1]. State rules on this have been moving, so check your own state’s current requirement.

A concept that appears repeatedly in state enforcement is the good faith examination: the requirement that a prescriber actually evaluate the patient rather than rubber-stamp an order. High-volume weight loss prescribing is where state boards have focused, because volume makes it easy to argue that no real evaluation occurred.

Step 3: The prescription is routed to a pharmacy

This is the step most people never think about, and the one that changes everything about what you receive.

If you are getting a branded medication — Wegovy, Ozempic, Zepbound, Foundayo — the prescription goes to a licensed retail or mail-order pharmacy, or to a manufacturer channel such as NovoCare Pharmacy or LillyDirect. You get the same pen or vial that a pharmacy counter would hand you, in manufacturer packaging, with a manufacturer lot number.

If you are getting a compounded medication, the prescription goes to a compounding pharmacy, which mixes it and ships a vial. The names that come up most often in the U.S. GLP-1 market are Empower Pharmacy, Hallandale Pharmacy, Olympia Pharmacy, Red Rock Pharmacy, Belmar Pharmacy, Strive Compounding Pharmacy, ProRx, and Apollo Care.

That distinction has consequences:

• Compounded drugs are not FDA approved. FDA does not review them for safety, effectiveness, or quality before they are sold [2].
• Compounding pharmacies have had recalls. ProRx semaglutide injections were recalled for lack of sterility assurance in 2025; Apollo Care recalled roughly 162,000 vials in July 2026 for particulate matter. FDA publishes a page listing compounding inspections, recalls, and other actions where you can look up a pharmacy by name [3].
• You cannot always tell who compounded it. In February 2026 FDA warned MEDVi that its website labeling implied MEDVi was the compounder when it was not [4].

So the single most useful question to ask a telehealth service before you pay is: which pharmacy fills this, and is it a 503A pharmacy or a 503B outsourcing facility? A legitimate operation will answer without hesitating.

Step 4: Shipping and what arrives

Branded product arrives in manufacturer packaging. Compounded product typically arrives as a vial, syringes, and alcohol wipes, often with a beyond-use date rather than a manufacturer expiration date.

Two practical points:

Cold chain. GLP-1 products generally require refrigeration. Check what the shipping materials say about temperature and what to do if a package arrives warm. A program that has no answer to that question has a gap.

Dose measurement. If you receive a vial rather than a prefilled pen, you will be drawing each dose yourself. This is where the best-documented harm in this category comes from. FDA has alerted providers and patients to overdoses caused by patients measuring the wrong volume, including ten-fold errors driven by confusion between milligrams, milliliters, and insulin “units.” Nobody should be figuring that out from a forum post. Ask the prescriber to walk you through it and confirm what you understood.

Step 5: Follow-up, refills, and cancellation

The follow-up structure is where cash-pay platforms differ most.

A clinical program checks in on side effects, weight, and whether a dose adjustment is warranted, and responds when you message. A storefront ships the next month automatically.

Cancellation deserves a paragraph of its own, because it has been an enforcement target. In December 2025 the FTC approved a final order against the telehealth company NextMed over GLP-1 weight loss marketing [5]. The allegations included hidden costs, undisclosed membership requirements, unsubstantiated weight loss claims, fabricated testimonials, manipulated reviews, failure to honor cancellation requests, and billing without proper consent. The order carried a $150,000 judgment and required clear disclosure of refund and cancellation terms up front, simple cancellation processes, and informed consent before charging.

Before you enroll, find the answers to: How do I cancel? Can I do it without a phone call? If I prepaid for six or twelve months, what happens?

What legitimate looks like, and what does not

Signs of a real clinical operation

• It states clearly whether the medication is FDA-approved or compounded.
• It names the prescribing clinician and their license.
• It tells you which pharmacy fills your prescription.
• It asks about your other medications and relevant medical and family history.
• It has a real way to reach a clinician about a side effect.
• Total cost is disclosed up front, including membership, labs, and shipping.
• Cancellation is self-service.
• It appears on a manufacturer’s recognized telehealth list, such as Novo Nordisk’s or LillyDirect’s [6][7]. That is not an endorsement of the clinicians, but it does mean the medicine sourcing has been vetted.

Red flags

• No prescription required. Prescription drugs require a prescription. Sites selling peptides “for research use only” have received FDA warning letters treating them as marketers of unapproved new drugs [8].
• Claims that a compounded product is generic, equivalent, or FDA approved. FDA has specifically identified these as false or misleading claims [2].
• Claims that the pharmacy is FDA-approved or FDA-licensed. No pharmacy is FDA-approved.
• A price that is only true if you prepay a year.
• No way to find out which pharmacy makes your medication.
• Cancellation only by phone, or a retention script before they will process it.
• Shipping from overseas, or payment only by cryptocurrency or bank transfer.

A structural issue worth knowing about

Most states prohibit a corporation from owning a medical practice or influencing a clinician’s medical judgment. This is called the corporate practice of medicine doctrine, and it is the reason telehealth companies are usually structured as a technology company contracting with a separate physician-owned entity.

In 2025 and 2026, drug manufacturers used that doctrine as a legal weapon. Eli Lilly’s April 2025 lawsuits against four telehealth companies alleged, among other things, that the platforms improperly influenced clinical decisions — including allegations that one company influenced the dosing and formulation of compounded tirzepatide for business reasons [9]. Novo Nordisk made similar allegations in its nationwide litigation campaign.

You do not need to track the litigation. The reason it matters to you as a patient is simple: if a platform’s economics depend on you getting a particular formulation from a particular pharmacy, the clinical recommendation you receive may not be independent of that. Asking “what else could I take, and why not that?” is a fair question.

Reporting a problem

If something goes wrong, there are three places to take it.

The prescribing clinician, first, for anything clinical.

FDA MedWatch, for adverse events and product problems. This matters more with compounded drugs than with branded ones, because state-licensed 503A pharmacies are not required to report adverse events the way manufacturers are. FDA had logged more than 1,700 adverse event reports naming compounded GLP-1s through May 31, 2026 and has said the true number is likely higher [10].

Your state board of pharmacy or medical board, for concerns about how a pharmacy or prescriber operated.

The short version

Getting a GLP-1 prescription online is legal, normal, and often the most practical route. What varies enormously is what you actually receive at the end of it.

Three questions carry most of the weight:

1. Is the medication FDA-approved or compounded?
2. Which pharmacy fills it, and what is its inspection and recall record?
3. What is the total monthly cost, and how do I cancel?

Everything else is detail. And whether a GLP-1 is right for you at all is a conversation for a healthcare provider, not a questionnaire.

Sources

1. State Telehealth Policies for Online Prescribing — Center for Connected Health Policy
2. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs — FDA
3. Compounding: Inspections, Recalls, and other Actions — FDA
4. Warning Letter: MEDVi, LLC dba MEDVi, February 20, 2026 — FDA
5. FTC Approves Final Order against Telehealth Provider NextMed — Federal Trade Commission
6. Find a Doctor to Help with Weight Loss Treatment — NovoCare
7. Telehealth for Obesity — LillyDirect
8. Warning Letter: Gram Peptides, March 31, 2026 — FDA
9. Telehealth Companies Sued for Selling Compounded GLP-1 Drugs and Violations of Corporate Practice of Medicine Laws — Wilson Sonsini
10. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide — Drug Discovery & Development
11. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA